source
- Summit Therapeutics' ivonescimab misses interim goal, shares tumble 27% as trial setback raises doubtsSummit Therapeutics reported that its experimental immunotherapy ivonescimab failed to achieve statistical significance at an interim analysis of the late-stage HARMONi-3 trial in frontline non‑sma…
- Two biotech firms raise $556 million in combined IPOsSeaport Therapeutics and Hemab Therapeutics launched initial public offerings on Thursday, together bringing in $556.4 million to fund further development of their drug pipelines. Hemab Therapeuti…